Index

A
Amplicor Monitor HBV,
clinical impact of DNA quantification, 10, 11
interassay correlation, 8, 9
principles, 5
sensitivity and dynamic range, 7, 8
standardization, 9–11

B
Baculovirus–insect cell expression system,
DHBV carboxypeptidase D expression, 208, 209, 211
hepatitis B virus polymerase purification,
advantages, 272
affinity column preparation and chromatography, 274, 275
insect cell culture and infection, 274
materials, 273, 274
Bayer Versant HBV assay,
clinical impact of DNA quantification, 10, 11
interassay correlation, 8, 9
principles, 4
sensitivity and dynamic range, 7, 8
standardization, 9–11

C
Carboxypeptidase D (CPD),
DHBV preS,
binding assay,
cell-binding assay, 210, 211
fluorescence labeling of proteins, 208
in vitro assay, 210
overview, 203
carboxypeptidase D binding affinity, 200
carboxypeptidase D binding-induced conformational change, 201
features, 199, 200
domains, 199
duck hepatitis B virus receptor, 199
purification,
liver lysate protein,
overview, 201
preS immobilization and affinity chromatography, 207, 208, 211
para-amino-benzoyl-arginine immobilization and affinity chromatography, 207, 208
materials, 203–206, 210
recombinant protein,
baculovirus expression system, 208, 209, 211
expression in Escherichia coli, 206
nickel affinity chromatography, 206
overview, 201, 202
separation of oligomeric and monomeric forms, 209
viral proteins in binding, 199, 200
CID variants, see Core internal deletion variants
Core antigen, see HBcAg
Core internal deletion (CID) variants, hepatitis B virus, clinical significance, 152
defective interference assay using one-filter–three-probe Southern assay,
core-associated DNA preparation, 159
hybridization and detection, 160, 161
intracellular core particle preparation, 158, 159
materials, 157, 158
plasmid constructs, 158
principles, 153, 154, 157
probe preparation,
DEL85-specific probe, 160
full-length probe, 159
wild type-specific probe, 159, 160
defective interfering particles, characteristics, 151–153
examples in other viruses, 151
identification, 152, 157
mechanism of action, 151
replication defects and rescue, 152, 153
CPD, see Carboxypeptidase D

D
Defective interference (DI), see
Core internal deletion variants, hepatitis B virus
DHBV, see Duck hepatitis B virus
DI, see Defective interference
Digene Hybrid Capture II System, clinical impact of DNA quantification, 10, 11
interassay correlation, 8, 9
principles, 4, 5
sensitivity and dynamic range, 7, 8
standardization, 9–11
Duck hepatitis B virus (DHBV), polymerase, see Polymerase, duck hepatitis B virus
preS binding to carboxypeptidase D, see Carboxypeptidase D

E
e antigen, see HBeAg

G
Genostics HBV DNA Assay, clinical impact of DNA quantification, 10, 11
interassay correlation, 8, 9
principles, 3, 4
sensitivity and dynamic range, 7, 8
standardization, 9–11

H
HBcAg,
F97L mutation, complementation test for cis effect,
core-associated DNA preparation, 254
core particle preparation, 254
cotransfections, 253, 254
materials, 252, 253
overview, 251, 252
Southern blot analysis, 254, 255
complementation test for trans effect,
core-associated DNA preparation, 254
core particle preparation, 254
cotransfections, 253, 254
immature secretion, 249
materials, 252, 253
plus-strand DNA deficiency, 249, 251
Southern blot analysis, 254, 255
extracellular phenotype, 247, 249
intracellular phenotype, 247
functions, 227, 247
immunohistochemistry,
materials, 65–68
paraffin section preparation and staining, 67–69
principles, 65
phosphorylation analysis,
materials, 228, 229
phosphorous-32 metabolic labeling of cells, 230–232
sites, 228
transfection, 229–231
Western blot, 230–232
processing, 227, 228
promoter mutants,
overview, 235, 236
replication competence studies, core particle analysis, 243
hepatitis B virus dimer transfection studies, 242
materials, 237
principles, 240
protein marker analysis, 243, 244
RNA analysis, 243
whole genome PCR, cloning and transfection, 240–242
sequencing, 237, 239
HBeAg,
function, 228
immunohistochemistry,
materials, 65–68
paraffin section preparation and staining, 67–69
principles, 65
precore stop codon mutants,
clinical significance, 235, 236
genotyping with reverse hybridization assay, 239, 240
replication competence studies, core particle analysis, 243
materials, 237
pregenome expression vector transfection, 242
principles, 240
protein marker analysis, 243, 244
RNA analysis, 243
whole genome PCR, cloning and transfection, 240–242
sequencing, 237, 239
treatment of HBeAg-negative infections, 236
HBsAg,
clinical course of expression, 57
enzyme-linked immunosorbent assay, 59
genotyping, see Polymerase chain reaction
heterogeneity, 58
immunohistochemistry,
materials, 65–68
paraffin section preparation and staining, 67–69
principles, 65
Laurell electrophoresis for blood quantification, agarose slide preparation, 60–62 calibration, 60, 62 electrophoresis and detection, 61, 62 materials, 59, 60 principles, 58, 59 S gene consensus sequence, 134 structure, 57, 189 transient transfection studies, COS7 cell transfection, 193, 194, 197 endoglycosidase H treatment, 197 gel electrophoresis and autoradiography, 197, 198 harvest for direct immunoprecipitation, 194 immunoprecipitation, 195–197 materials, 191–193, 197 protease protection experiments, 194, 195 pulse/chase labeling, 194, 197 unit definition, 59 vaccine escape mutants, 116 HBV, see Hepatitis B virus HBxAg, apoptosis induction, 73, 74, 334 expression and function, 71–73, 333, 334 hepatocellular carcinoma role, 333, 334 immunostaining, frozen section staining, 79 materials, 74–76 paraffin section preparation, 76, 80 staining of tissue samples, 76, 77 transfected cell staining, 77, 78 p53 binding, 334 phosphorylation, 72 Western blot, electrophoresis, 79, 80 immunoblotting, 80 materials, 74–76 monolayer culture, 79 suspension culture, 79 tissue samples, 79 HCC, see Hepatocellular carcinoma HDV, see Hepatitis D virus Hepatitis B virus (HBV), core antigen, see HBcAg core internal deletion variants, see Core internal deletion variants, hepatitis B virus DNA assays, see Amplicor Monitor HBV; Bayer Versant HBV assay; Digene Hybrid Capture II System; Genostics HBV DNA Assay; In situ hybridization; Oligonucleotide probing, hepatitis B virus DNA; Polymerase chain reaction duck virus, see Duck hepatitis B virus e antigen, see HBeAg envelope proteins, see Large envelope protein; Middle envelope protein; Small envelope protein epidemiology, 175, 247, 271 genome, 303 genome mutation rates, 115, 116 genotypes and phylogenetic analysis, 117, 118, 123, 125, 176, 235
genotyping, see INNO-LiPA HBV Genotyping;
Polymerase chain reaction;
Restriction fragment length polymorphism analysis
infection establishment,
persistent infection, 329
transient infection, 328, 329
nucleoprotein transport, see
Nucleoprotein transport,
hepatitis B virus capsid particles
polymerase, see Polymerase,
duck hepatitis B virus;
Polymerase, hepatitis B virus
replication cycle, 41, 42, 327, 328
RNA detection, see Reverse transcriptase-polymerase chain reaction
serotyping, 115, 175
surface antigen, see HBsAg
transcriptional control analysis, see Transient transfection
variant classes, 116
x antigen, see HBxAg
Hepatitis D virus (HDV),
antigen,
large antigen, see L-HDVAg
nuclear staining patterns, 99, 103
small antigen, see S-HDVAg
genome, 85
replication, 85
RNA detection, see In situ hybridization; Reverse transcriptase-polymerase chain reaction
Hepatocellular carcinoma (HCC),
hepatitis B virus antigen
expression as risk factor, 72
hepatitis B virus induction mechanisms,
hit-and-run mutagenesis, 332
insulin-like growth factor-2 expression, 331, 332
liver cell death and regeneration, 329, 330
oncogene activation, 330, 331
topoisoamerase I role, 332
X protein, 333, 334

I

IGF-2, see Insulin-like growth factor-2

Immunofluorescence microscopy, hepatitis D virus antigen,
materials, 99–101
nuclear staining patterns, 99, 103
polymerase of duck hepatitis B virus, 284, 289–291

Immunohistochemistry, see HBcAg; HBeAg; HBsAg; HBxAg; L-HDVAg; S-HDVAg

INNO-LiPA HBV Genotyping, hybridization,
Auto-LiPA procedure, 183, 184
manual procedure,
denaturation and hybridization, 182, 185, 186
reagent preparation, 181, 182
stringent wash, 182, 183, 185, 186
interpretation, 184
materials, 178, 179, 184, 185
nucleic acid isolation, 180, 185
polymerase chain reaction,
nested amplification, 181
outer amplification, 180, 181
principles, 176–178, 184
strip storage, 184

*In situ* hybridization,
hepatitis B virus DNA in liver
paraffin sections,
digoxigenin-labeled probe
preparation, 53, 54
hybridization and detection, 53–55
materials, 51–53
principles, 51
hepatitis D virus RNA in liver
paraffin sections,
hybridization and digoxigenin
detection, 97, 98
materials, 95–97
paraffin section digestion, 97, 98
principles, 95
probe design, 95

Insulin-like growth factor-2 (IGF-2),
hepatocellular carcinoma
expression, 331, 332

*L*

Lamivudine, viral mutations in
resistance, 125, 126, 132, 136–139

Large envelope (L) protein,
expression, 189, 190
processing, 189–191
transient transfection studies,
COS7 cell transfection, 193,
194, 197
endoglycosidase H treatment, 197
gel electrophoresis and
autoradiography, 197, 198
harvest for direct
immunoprecipitation, 194
immunoprecipitation, 195–197
materials, 191–193, 197
protease protection
experiments, 194, 195
pulse/chase labeling, 194, 197
Large hepatitis D antigen, *see*
L-HDVAg
Laurell electrophoresis, *see* HBsAg
L-HDVAg,
expression, 99, 107
function, 99, 107
immunofluorescence microscopy,
materials, 99–101
nuclear staining patterns, 99, 103
immunohistochemical detection,
digestion of paraffin sections,
108–110
materials, 108
principles, 107, 108
staining, 109, 110
Western blot,
cell culture, 101
gel electrophoresis and
immunoblotting, 102
materials, 99–101
serum sample preparation, 102
Line probe assay, *see* INNO-LiPA
HBV Genotyping
L protein, *see* Large envelope
protein

*M*

Middle envelope (M) protein,
expression, 189, 190
internal deletions,
clinical significance, 165, 170
hypermodification, 166, 170
Western blot characterization,
cell culture, 168, 170, 171
gel electrophoresis and
blotting, 170, 171
plasmids, 166–168, 170
sample preparation, 169, 171
solutions, 168, 169
transfections, 169
pre S2 gene region, 165
processing, 189–191
transient transfection studies,
COS7 cell transfection, 193,
194, 197
endoglycosidase H treatment, 197
gel electrophoresis and
autoradiography, 197, 198
harvest for direct
immunoprecipitation, 194
immunoprecipitation, 195–197
materials, 191–193, 197
protease protection
experiments, 194, 195
pulse/chase labeling, 194, 197
M protein, see Middle envelope
protein

N
Nucleoprotein transport, hepatitis B
virus capsid particles,
cell culture, 218, 223, 224
cell permeabilization, 218, 219, 224
cell culture, 218, 223, 224
cell permeabilization, 218, 219, 224
cell cycle transport processes,
213, 214
materials, 217, 218
nuclear import overview, 214, 215
overview of study techniques, 214
phosphorylative regulation, 216
polymerase role, 215, 216
transport reactions, 219, 220, 224
troubleshooting,
cell loss, 222
staining, 222, 223

O
Oligonucleotide probing, hepatitis B
virus DNA,
hybridization and washing
conditions, 25–27
materials, 23–26
membrane preparation, 26
principles, 21–23
probe preparation, 25, 26
sensitivity, 21

P
PCR, see Polymerase chain reaction
Polymerase, duck hepatitis B virus,
activities, 259
cell-free expression system,
coupling of transcription and
translation, 264
history of study, 261
materials, 262, 263, 265
protein priming, in vitro, 264–267
transcription reaction, 264
transcription template
preparation, 263, 264
translation reaction, 264
functions, 259, 261, 281
intracellular localization,
anti-bodies, 281, 282
immunofluorescence
microscopy, 284, 289–291
immunoprecipitation of
nonenveloped
polymerase from cell
lysates, 289, 291
materials, 285–288
Western blot,
cell lysate preparation, 288, 290
nonencapsidated polymerase in transfected cells, 288, 290
overview, 282–284
phosphorylation, 282
reconstitution of ε-dependent replication initiation,
De RNA synthesis, 322, 323
materials, 318, 320, 323
NusDP preparation,
expression vector cloning, 318, 320
large-scale expression, 321
lysate preparation, 321, 323
nickel affinity chromatography, 321, 323
selection of transformants, 320, 321
transformation in E. coli, 320, 323
overview, 315–318
priming assay, 322, 323
reconstitution conditions, 322, 323
structure, 259, 260, 281
Polymerase, hepatitis B virus,
activities, 71, 295
antiviral therapy resistance
mutations, 125, 126, 132, 136–139
assays,
core–pol endogenous polymerase assay, 276, 277
in vitro priming assay, 275–277
overview, 272
serum assay,
gel electrophoresis, 299–301
incubation conditions, 298–300
materials, 297–299
principles, 296, 297
sample collection, 298, 299
consensus sequence, 133
duck enzyme, see Polymerase,
duck hepatitis B virus functions, 271, 272, 295, 296
nucleoprotein transport role, 215, 216
purification from baculovirus–insect cell system,
advantages, 272
affinity column preparation and chromatography, 274, 275
insect cell culture and infection, 274
materials, 273, 274
Polymerase chain reaction (PCR), hepatitis B virus covalently closed circular DNA quantification,
contamination prevention, 49
controls, 45
liver sample preparation, 46, 49
master hybridization probes procedure,
β-globin gene amplification and quantification, 48
LightCycler amplification and quantification, 44, 45, 47, 49
master mix preparation, 47, 49
materials, 44, 45
principles, 42–44
quantification of covalently closed circular DNA, 48
rationale, 41, 42
standards, 45, 46
SYBR Green 1 procedure,
LightCycler amplification and quantification, 44, 47, 49
master mix preparation, 46, 49
template addition, 46, 49

INNO-LiPA HBV Genotyping, see INNO-LiPA HBV Genotyping RNA detection, see Reverse transcriptase-polymerase chain reaction PreS, see Duck hepatitis B virus PreS2, see Middle envelope protein, hepatitis B virus

R
Restriction fragment length polymorphism (RFLP) analysis, hepatitis B virus genotyping, 116 Reverse transcriptase-polymerase chain reaction (RT-PCR), hepatitis B virus RNA detection, amplification reactions, 32, 33 f RNA assay, 33, 39 f/tr RNA assay, 34, 36, 39 hybridization conditions, 31, 32 materials, 29, 30 nucleic acid extraction, 30, 39 primers, 30, 31 principles, 29 probe preparation, 30–32 quantitative analysis, 36, 37 serum sample collection, 30, 37 tr RNA assay, 34 hepatitis D virus RNA detection, amplification reactions, 90, 91 clinical utility, 87 gel electrophoresis analysis of products, 91 materials, 87–89, 91 nucleic acid isolation from serum, 89, 90 primers, 88
reverse transcription, 90
sensitivity, 86, 87
target selection, 86

RFLP analysis, see Restriction fragment length polymorphism analysis

Ribonuclease protection assay, hepatitis B virus transcriptional control studies, 309, 310, 312

RT-PCR, see Reverse transcriptase-polymerase chain reaction

S
S gene, see HBsAg; Polymerase chain reaction

S-HDVAg,
expression, 99, 107
function, 107
immunofluorescence microscopy, materials, 99–101
nuclear staining patterns, 99, 103
immunohistochemical detection, digestion of paraffin sections, 108–110
materials, 108
principles, 107, 108
staining, 109, 110

Western blot,
cell culture, 101
gel electrophoresis and immunoblotting, 102
materials, 99–101
serum sample preparation, 102

Small envelope (S) protein,
expression, 189, 190
processing, 189–191
transient transfection studies,
COS7 cell transfection, 193, 194, 197

endoglycosidase H treatment, 197
gel electrophoresis and autoradiography, 197, 198
harvest for direct immunoprecipitation, 194
immunoprecipitation, 195–197 materials, 191–193, 197
protease protection experiments, 194, 195
pulse/chase labeling, 194, 197
Small hepatitis D antigen, see S-HDVAg

Southern blot,
HBcAg F97L mutation complementation tests, 254, 255
hepatitis B virus core internal deletion variant defective interference assay using one-filter–three-probe assay, core-associated DNA preparation, 159
hybridization and detection, 160, 161
intracellular core particle preparation, 158, 159
materials, 157, 158
plasmid constructs, 158
principles, 153, 154, 157
probe preparation,
DEL85-specific probe, 160
full-length probe, 159
wild type-specific probe, 159, 160

S protein, see Small envelope protein

Surface antigen, see HBsAg

T
Topoisomerase I, hepatocellular carcinoma role, 332
Transplant transfection, hepatitis B virus antigen and envelope protein processing studies,
COS7 cell transfection, 193, 194, 197
endoglycosidase H treatment, 197
gel electrophoresis and autoradiography, 197, 198
harvest for direct immunoprecipitation, 194
immunoprecipitation, 195–197
materials, 191–193, 197
protease protection experiments, 194, 195
pulse/chase labeling, 194, 197
hepatitis B virus transcriptional control studies,
β-galactosidase assay, 308, 311
cell lysis for reporter assay, 307, 308, 311
luciferase assay, 308, 311
luciferase reporter transfection, 307, 311
materials, 305, 306, 311
overview, 304, 305
RNA analysis,
cell lysis, 309, 311, 312
materials, 306, 307, 311
ribonuclease protection assay, 309, 310, 312
transfection, 309

Western blot,
HBcAg phosphoproteins, 230–232
HBxAg,
electrophoresis, 79, 80
immunoblotting, 80
materials, 74–76
monolayer culture, 79
suspension culture, 79
tissue samples, 79
hepatitis B virus middle envelope protein internal deletion characterization,
cell culture, 168, 170, 171
gel electrophoresis and blotting, 170, 171
plasmids, 166–168, 170
sample preparation, 169, 171
solutions, 168, 169
transfections, 169
hepatitis D virus antigen,
cell culture, 101
gel electrophoresis and immunoblotting of small and large antigens, 102
materials, 99–101
serum sample preparation, 102
polymerase of duck hepatitis B virus,
cell lysate preparation, 288, 290
nonencapsidated polymerase in transfected cells, 288, 290
overview, 282–284

X
X antigen, see HBxAg